首页 > 市场调查报告书 > 製药

癌症分子标靶治疗学

市场调查报告书

商品编码

1643946

CD70标靶治疗药的全球市场:临床试验和市场机会(2025年)

Global CD70 Targeting Therapies Clinical Trials & Market Opportunity Insight 2025

出版日期: 2025年01月01日 | 出版商:

KuicK Research | 英文 150 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

针对 CD70 的药物正迅速成为治疗各种癌症和免疫相关疾病的一种有希望的策略，并且正在彻底改变治疗模式。细胞表面蛋白 CD70 在调节免疫系统方面至关重要，使其成为旨在选择性攻击患病细胞同时保护健康组织的疗法的理想标靶。精准医疗的措施在肿瘤学领域尤其重要，因为化疗和放射疗法等传统治疗方法往往具有严重的副作用且疗效有限。

在临床实践中，针对CD70的疗法在治疗血液系统恶性肿瘤，特别是急性髓细胞白血病（AML）和肾细胞癌（RCC）等实体肿瘤方面显示出巨大的潜力。急性骨髓性白血病很难透过标准治疗来控制，尤其是对于不适合强化化疗的患者。针对 CD70 标靶治疗的临床试验显示出解决此问题的前景，单株抗体和工程细胞疗法为治疗选择较少的患者带来了新的希望。目前处于临床开发阶段的最先进的 CD70 标靶疗法是 Argenx 发现的 cusatuzumab，该疗法目前正处于与化疗联合治疗 AML 患者的 2 期试验阶段。这种联合策略旨在透过解决抗药性机制来提高库沙珠单抗的疗效，从而改善患者的整体治疗效果。

CD70标靶治疗的应用不仅限于癌症治疗。这些治疗方法也正在针对自体免疫疾病、病毒感染和移植物抗宿主疾病 (GvHD) 进行研究，但研究仍处于早期阶段。在免疫反应失调的情况下，针对 CD70 的药物有可能调节免疫系统并恢復正常的免疫功能。扩大治疗应用将大大增加人们对该领域的兴趣，因为它扩大了这些疗法的潜在市场。

中国已成为全球 CD70 标靶治疗领域的重要竞争对手。透过增加投资和与国际公司的合作，该国蓬勃发展的生物技术产业得到了推动，从而推动了创新疗法的快速发展。中国的研究机构正在加强对临床试验的参与度，本土生物技术公司在 CD70 标靶疗法商业化方面也取得了进展。

CD70 标靶治疗市场竞争日益激烈，刺激创新，包括 Allogene Therapeutics、Seagen（辉瑞）和 CRISPR Therapeutics 在内的多家公司正在开发新型疗法。这些公司正在进行全面的临床前和临床研究，以评估治疗的安全性和有效性，从而提升 CD70 标靶治疗的潜力。随着越来越多的治疗方法进入临床试验并产生积极成果，CD70 标靶治疗的商业机会正在扩大。

本报告提供全球CD70标靶治疗药市场相关调查，提供市场概要，以及药物趋势，临床试验趋势，各地区趋势，及加入此市场的主要企业竞争情形等资讯。

CD70 Targeting Therapies In Clinical Trials: > 20 Therapies
CD 70 Targeting Therapies Clinical Trials Insight By Company, Country, Indication and Phase
Insight On CD70 Targeting Therapy Technology Platforms
FDA & EMA Designations Insight: Orphan, FTD, RMAT Designation
Global & Regional Market Development Insight
Combination Strategies For CD70 Targeting Therapies

CD70 targeting therapies are rapidly gaining recognition as a promising strategy for the treatment of various cancers and immune-related disorders, significantly transforming the therapeutic landscape. CD70, a cell surface protein, is crucial in regulating the immune system, making it an optimal target for therapies designed to selectively attack diseased cells while preserving healthy tissues. This movement towards precision medicine is particularly vital in oncology, where traditional treatments such as chemotherapy and radiation often lead to severe side effects and limited effectiveness.

In clinical practice, CD70 targeting therapies are demonstrating considerable potential in treating hematological malignancies, particularly acute myeloid leukemia (AML), as well as solid tumors like renal cell carcinoma (RCC). AML is particularly challenging to manage with standard therapies, especially in patients who are unsuitable for intensive chemotherapy. Clinical trials focused on CD70 targeted therapies have shown promise in addressing this issue, with monoclonal antibodies and engineered cell therapies offering new hope for patients with few treatment options. The most advanced CD70-targeting therapy currently in clinical development is Cusatuzumab, created by argenx, which is presently undergoing Phase 2 trials in conjunction with chemotherapeutic agents for AML patients. This combination strategy seeks to enhance the effectiveness of Cusatuzumab by tackling resistance mechanisms and improving overall patient outcomes.

The application of CD70 targeting therapies extends beyond cancer treatment. These therapies are also being investigated for autoimmune diseases, viral infections, and graft-versus-host disease (GvHD), although they remain in the early stages of research. In these contexts, where immune responses are dysfunctional, CD70 targeting agents hold the potential to modulate the immune system and restore normal immune function. The expansion of therapeutic applications significantly fuels interest in this sector, as it broadens the potential market for these treatments.

In commercial terms, the US stands as hub for CD70 targeting therapy research and development. A robust ecosystem comprising biotechnology companies, pharmaceutical enterprises, and research institutions has driven the advancement of these therapies. Notable institutions such as Baylor College of Medicine, the National Institutes of Health, and cancer centers like City of Hope are conducting crucial clinical trials. Furthermore, regulatory support from the US FDA, including the Fast Track Designation for Adicet Bio's ADI-270 and the Regenerative Medicine Advanced Therapy designation for Allogene Therapeutics' ALLO-316, has expedited the development and commercialization processes. This regulatory endorsement is vital in facilitating access to new treatments, positioning the US as the heart for both clinical development and market introduction.

China is emerging as a significant contender in the global CD70 targeting therapy landscape. The country's rapidly growing biotechnology sector, bolstered by increased investments and partnerships with international companies, has enabled swift advancements in innovative therapies. Chinese research institutions are increasingly involved in clinical trials, while local biotech firms are progressing towards the commercialization of CD70 targeting therapies.

The intensifying competition within the CD70 targeting therapy market is fostering innovation, with several companies, including Allogene Therapeutics, Seagen (Pfizer), and CRISPR Therapeutics, developing novel treatments. These organizations are engaged in comprehensive preclinical and clinical research to assess the safety and efficacy of their therapies, thereby enhancing the therapeutic potential of CD70 targeted interventions. As more therapies enter clinical trials and yield favorable outcomes, the commercial opportunities for CD70 targeting therapies are expanding.

In conclusion, the integration of favorable clinical results and a dynamic commercial landscape establishes CD70 targeting therapies as a crucial component of the future of precision medicine. As an increasing number of companies and research organizations dedicate resources to these therapies, their capacity to tackle a diverse array of diseases expands, indicating the prospect of both clinical and commercial achievements ahead.

1. Introduction To CD70 Targeting Therapy

1.1 CD70 Targeting Therapy Overview
1.2 The Prerequisite For CD70 Targeting Therapy
1.3 Dual Role of CD70 As Diagnostic & Prognostic Biomarker

2. CD70 Targeting Therapeutic Approaches

2.1 Monoclonal Antibody
2.2 Bispecific Antibody
2.3 Tetraspecific Antibody
2.4 CAR T Cell Therapy
2.5 Antibody Drug Conjugate
2.6 CAR-NK Therapy

3. CD70 Targeting Therapies Clinical Research & Development By Indications

3.1 Leukemia
3.2 Lymphoma
3.3 Gynecologic Cancer
3.4 Renal Cell Carcinoma
3.5 Lung Cancer
3.6 Autoimmune & Inflammatory Disease
3.7 Viral Infections

4. Global CD70 Targeting Therapies Clinical Trials Overview

4.1 By Phase
4.2 By Country
4.3 By Company
4.4 By Indication
4.5 By Priority Status
4.6 Patient Segment

5. CD70 Targeting Therapies Regulatory Designations: Fast Track & Orphan Designation

6. Global CD70 Targeting Therapies Clinical Trials Insight

6.1 Preclinical
6.2 Phase I
6.3 Phase I/II
6.4 Phase II

7. CD70 Targeting Therapies Development Platforms By Company & Technology

7.1 AlloCAR T Platform
7.2 Gamma Delta Cell Platform
7.3 Tailwind Platform
7.4 DARPin Platform
7.5 SIMPLE Antibody Platform
7.6 Potelligent Technology
7.7 Off The Shelf Allogeneic Manufacturing

8. Global CD70 Targeting Therapies Current Market Trend & Developments

8.1 Current Market Outline
8.2 Future Market Forecast

9. CD70 Targeting Therapies Market Opportunity & Clinical Trends By Region

9.1 US
9.2 China
9.3 Europe

10. Combination Strategies For CD70 Targeting Therapies

10.1 In Combination With Immunotherapy
10.2 In Combination With Epigenetic Modulators
10.3 In Combination With Targeted Therapy
10.4 In Combination With Oncolytic Virus Therapy
10.5 In Combination With Chemotherapy

11. Global CD70 Targeting Therapies Market Dynamics

11.1 Market Drivers
11.2 Market Challenges

12. Competitive Landscape

12.1 Adaptimmune
12.2 Adicet Bio
12.3 Allogene Therapeutics
12.4 Ambrx (Johnson & Johnson)
12.5 Chongqing Precision Biotech
12.6 Chinook Therapeutics (Novartis)
12.7 CRISPR Therapeutics
12.8 ImmuneOnco Biopharma
12.9 Pfizer
12.10 Poseida Therapeutics

简介目录图表

List of Figures

Figure 1-1: Introduction To CD70 Protein
Figure 1-2: History & Development Of CD70 Targeting Therapies
Figure 1-3: CD70 As Diagnostic & Prognostic Marker In Cancer
Figure 2-1: Approaches For Targeting CD70
Figure 3-1: Role Of CD70 In Leukemia
Figure 3-2: Molecular Partners - MP0533
Figure 3-3: MP0533 Phase I/II (NCT05673057) Study - Initiation & Completion Year
Figure 3-4: Cusatuzumab Phase II (NCT04023526) Study - Initiation & Completion Year
Figure 3-5: Cusatuzumab Phase II (NCT06384261) Study - Initiation & Completion Year
Figure 3-6: Role Of CD70 In Leukemia
Figure 3-7: CAR.70/IL-15 NK Cell Therapy Phase II (NCT05092451) Study - Initiation & Completion Year
Figure 3-8: CB CAR-NK019 Phase I (NCT05667155) Study - Initiation & Completion Year
Figure 3-9: CD70 CAR T Therapy Early Phase I (NCT04662294) Study - Initiation & Completion Year
Figure 3-10: Lymphoma: Key Market Players Conducting CD70 Clinical Research
Figure 3-11: Role Of CD70 In Gynecologic Cancers
Figure 3-12: CD70 CAR-T Therapy Phase I (NCT06010875) Study - Initiation & Completion Year
Figure 3-13: Anti-hCD70 CAR transduced PBL Phase I/II Study - Initiation & Completion Year
Figure 3-14: CTX131 Phase I (NCT05795595) Study - Initiation & Completion Year
Figure 3-15: Role Of CD70 In Renal Cell Carcinoma
Figure 3-16: Research By Allogene Therapeutics
Figure 3-17: TRAVERSE Phase 1 (NCT04696731) Study - Initiation & Completion Year
Figure 3-18: CTX131 Phase I/II (NCT05795595) Study - Initiation & Completion Year
Figure 3-19: CTX131 Phase I/II (NCT05795595) Study - Initiation & Completion Year
Figure 3-20: Role Of CD70 In Lung Cancer
Figure 3-21: Role Of CD70 In Autoimmune & Inflammatory Diseases
Figure 3-22: Role Of CD70 In Autoimmune & Inflammatory Diseases
Figure 4-1: Global - CD70 Targeting Therapies Clinical Trials By Phase (Numbers), 2025
Figure 4-2: Global - CD70 Targeting Therapies Clinical Trials By Country (Numbers), 2025
Figure 4-3: Global - CD70 Targeting Therapies Clinical Trials By Company (Numbers), 2025
Figure 4-4: Global - CD70 Targeting Therapies Clinical Trials By Indication (Numbers), 2025
Figure 4-5: Global - CD70 Targeting Therapies Clinical Trials By Priority Status (Numbers), 2025
Figure 4-6: Global - CD70 Targeting Therapies Clinical Trials By Patient Segment (Numbers), 2025
Figure 7-1: Allogene Therapeutics - AlloCAR T Platform
Figure 7-2: Adicet Bio - Gamma Delta Cell Platform
Figure 7-3: ADI-270 - CD70 CAR Yδ T Cell Therapy
Figure 7-4: Catamaran Bio - Tailwind Platform
Figure 7-5: Molecular Partners - DARPin Platform
Figure 7-6: Nkarta - CAR-NK Cells
Figure 7-7: Nkarta - Proprietary CAR-NK Cells Manufacturing Process
Figure 8-1: CD70 Targeting Therapy Current Market - Guiding Factors
Figure 8-2: Key Players In CD70 Market
Figure 8-3: CD70 Targeting Therapy Market Future - Influencing Factors
Figure 10-1: Combinations Of CD70 Therapy With Other Therapies
Figure 11-1: Global CD70 Targeting Therapy Market - Drivers
Figure 11-2: Global CD70 Targeting Therapy Market - Challenges

List of Tables

Table 6-1: CD70 Targeting Therapies With Regulatory Designations

02-2729-4219

+886-2-2729-4219

License/价格

CD70标靶治疗药的全球市场:临床试验和市场机会(2025年)

Global CD70 Targeting Therapies Clinical Trials & Market Opportunity Insight 2025

目录

第1章 CD70标靶治疗药的简介

第2章把CD70作为标的治疗方法

第3章 CD70标靶治疗药临床研究开发

第4章全球CD70标靶治疗药临床试验概要

第5章 CD70标靶治疗药的法规指定:贸易快速审批和罕见疾病用医药品的指定

第6章世界CD70标靶治疗药临床试验的洞察

第7章 CD70标靶治疗药开发平台(各企业·各技术)

第8章全球CD70标靶治疗药的目前市场趋势与开发

第9章 CD70标靶治疗药的市场机会和各地区的临床趋势

第10章 CD70标靶治疗药的组合策略

第11章全球CD70标靶治疗市场动态

第12章竞争情形